Feed / DOCS

Doximity, Inc.

DOCS

Healthcare · 24.72 +2.2% today

Isolated · not yet confirmedMarket checked 10 Sept, 15:55 GMT-4

Market read

Doximity, Inc.'s current read is isolated; its market group is not confirming.

The latest filing is mixed. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.

What changed
  • Revenue increased 13.1% versus the comparable filing period.
  • Operating margin fell 6.6 percentage points.
Company+2.2% todayVolume comparison unavailable
Market group0 of 4 activeGrowth Stocks · unavailable
Disclosed network0 of 4 confirmingNo filing-linked name is confirming now
What would change this read
  • R&D expense increased $37.7M for FY2026, primarily driven by a $28.6M increase in stock-based compensation tied to new service- and performance-based awards.

Invalidation: The isolated read changes if DOCS's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Health Information Services

The latest filing is mixed. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.

Evidence that supports
  • Revenue increased 13.1% versus the comparable filing period.
  • Operating cash flow covered net income at 1.67x, improving versus the comparable period.
Evidence that challenges
  • Operating margin fell 6.6 percentage points.
  • Gross margin fell 1.1 percentage points.
  • Net margin fell 8.7 percentage points.
What would clarify the read
  • R&D expense increased $37.7M for FY2026, primarily driven by a $28.6M increase in stock-based compensation tied to new service- and performance-based awards.

Company research

Understand the business, not just the ticker

As of Sep 11, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods7
Price observations327
Usable filing statements111
Verified relationships4
Evidence supporting the case
  • Latest annual revenue changed +13.1% year over year.
  • Operating cash flow covered net income at 1.67x in the latest annual period.
Evidence challenging the case
  • Operating margin changed -6.6 percentage points in the latest annual period.
  • Net margin changed -8.7 percentage points in the latest annual period.
Questions before a position
  • P/E is 62% below the available filing-peer median; determine whether growth and quality justify the difference.
  • EV/sales is 241% above the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context

Price as of Sep 10, 2026

24.72
6m+0.3%12m-64.4%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2022-03-31$343.5M+66.0%$0.70
2023-03-31$419.1M+22.0%$0.53+11.7%
2024-03-31$475.4M+13.5%$0.72-3.6%
2025-03-31$570.4M+20.0%$1.11-2.2%
2026-03-31$644.9M+13.1%$0.98-1.1%

What management says matters

Persistent and emerging business drivers

Product pipeline and R&Dnegative · 2 filings
This increase was primarily driven by reduced tax deductions from stock award activities and lower research and development tax credits, partially offset by lower income before taxes.
10-Q · Aug 6, 2026
Restructuring and cost reductionsmixed · 1 filings
Any impairment to the associated right-of-use assets and underlying property and equipment as a result of a sublease is recognized in the period the sublease is executed and recorded in the consolidated statements of operations.
10-K · May 19, 2026

Valuation discipline

Descriptive valuation snapshot

Price/sales 7.6× · EV/sales 7.3×. Comparisons use only industry-matched filing peers.

Scenario scaffold

Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.

Price action

How the market is pricing the story

24.72+2.2% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for DOCS. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Latest filing assessment · baseline

The latest filing presents a mixed picture

10-K filed 2026-05-19 against the comparable filing from 2025-05-20.

mixed
OperationsmixedEvidence score 0
liquidityconstructiveEvidence score +1
valuationmixed

What improved

  • Revenue increased 13.1% versus the comparable filing period.
  • Operating cash flow covered net income at 1.67x, improving versus the comparable period.

What weakened

  • Operating margin fell 6.6 percentage points.
  • Gross margin fell 1.1 percentage points.
  • Net margin fell 8.7 percentage points.

Filing receipts

Cost of revenue, gross profit, and gross margin Fiscal Year Ended March 31, Change 2026 2025 $ % (in thousands, except percentages) Cost of revenue $ 70,326 $ 55,874 $ 14,452 26 % Gross profit $ 574,537 $ 514,525 $ 60,012 12 % Gross margin 89 % 90 % Cost of revenue for the fiscal year ended March 31, 2026 increased $14.5 million as compared to the fiscal year ended 2025, primarily driven by a $5.6 million increase in hosting and software costs and a $2.5 million increase related to amortization of an acquired intangible and internally developed software.

Sales and marketing Fiscal Year Ended March 31, Change 2026 2025 $ % (in thousands, except percentages) Sales and marketing $ 163,648 $ 145,713 $ 17,935 12 % Sales and marketing expense for the fiscal year ended March 31, 2026 increased $17.9 million as compared to the fiscal year ended 2025, primarily driven by a $13.1 million increase in stock-based compensation as a result of new awards granted to new hires and existing employees, and a $6 million increase in marketing activities.

Operating Expenses Research and development Fiscal Year Ended March 31, Change 2026 2025 $ % (in thousands, except percentages) Research and development $ 130,702 $ 93,038 $ 37,664 40 % Research and development expense for the fiscal year ended March 31, 2026 increased $37.7 million as compared to the fiscal year ended 2025, primarily driven by a $28.6 million increase in stock-based compensation as a result of new service-based as well as performance-based awards granted to new hires and existing employees, a $4.9 million increase in personnel costs due to merit increases and increase in average headcount, a $3.7 million increase in third-party contractor costs, a $1.5 million increase in...

Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.

Business ecosystem

The relationships behind DOCS

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MSFTMicrosoft CorporationpartnerMay 19, 2026

This includes providers of communication solutions, such as Zoom Video Communications and Microsoft Teams, and dedicated telehealth services, such as Teladoc Health and American Well.

AMWLFiling-linked namecompetitorMay 19, 2026

This includes providers of communication solutions, such as Zoom Video Communications and Microsoft Teams, and dedicated telehealth services, such as Teladoc Health and American Well.

TDOCTeladoc Health, Inc.competitorMay 19, 2026

This includes providers of communication solutions, such as Zoom Video Communications and Microsoft Teams, and dedicated telehealth services, such as Teladoc Health and American Well.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

DOCS is currently a Leader in the organic co-movement group Growth Stocks. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.